Blood proteins

Cerus Corporation Announces CMS Has Granted New Technology Add-On Payment for INTERCEPT Fibrinogen Complex

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, General Health, Health, Medical Supplies, Blood, Proteins, Branches of biology, Coagulation system, Acute-phase proteins, Blood proteins, Federal assistance in the United States, Healthcare reform in the United States, Cerus Corporation, Fibrinogen, Prospective payment system, Factor I deficiency

Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System (IPPS).

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System (IPPS).
  • The NTAP was granted under CMS alternative NTAP pathway, which recognizes the transformative nature of products granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).
  • The U.S. FDA granted approval of the INTERCEPT Blood System for Cryoprecipitation, which is used to produce INTERCEPT Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency, in November 2020.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

New Studies Demonstrate Role of High-Flux Dialyzers in Managing Albumin

Retrieved on: 
Thursday, July 29, 2021
Blood proteins, Branches of biology, Medicine, Hypoalbuminemia, Anatomy, Serum albumin, Serum, Albumin, Hemodialysis

This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.

Key Points: 
  • This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.
  • "This study further demonstrates that high-flux dialyzers can play a role in increasing albumin levels, and especially for those patients with higher body mass index and inflammation."
  • "These results further reinforce the important role that high-flux dialyzers like Optiflux can play in helping address the potential dangers of low serum albumin levels."
  • The authors note that "excessive" loss of albumin is a theoretical concern with the chronic use of increasingly permeable dialyzers.

Cerus Announces Collaboration with LifeSouth Community Blood Centers to Manufacture INTERCEPT® Fibrinogen Complex

Retrieved on: 
Wednesday, June 30, 2021
Medical Supplies, Medical devices, Health, Hospitals, Cardiology, Biotechnology, Blood, Proteins, Anatomy, Acute-phase proteins, Blood proteins, Coagulation system, Fibrinogen, Transfusion medicine, Fibrin, Cryoprecipitate, Draft:Cerus Corporation

Cerus Corporation (NASDAQ: CERS) announced today an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT Fibrinogen Complex, the companys pathogen reduced cryoprecipitated fibrinogen complex product.

Key Points: 
  • Cerus Corporation (NASDAQ: CERS) announced today an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT Fibrinogen Complex, the companys pathogen reduced cryoprecipitated fibrinogen complex product.
  • LifeSouth is the fifth production partner for INTERCEPT Fibrinogen Complex, enabling the initial commercial launch of the product to expand into the state of Florida.
  • We are delighted to add LifeSouth as a blood center manufacturing partner for INTERCEPT Fibrinogen Complex, stated Elan Weiner, general manager of Cerus Therapeutics.
  • We believe INTERCEPT Fibrinogen Complex is an exciting innovation in transfusion medicine, and we are pleased to partner with Cerus in the Florida market.

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Iron metabolism, Medical specialties, Clinical medicine, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Iron overload, Erythropoietin

Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.

Key Points: 
  • Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.
  • We are pleased to be able to present multiple posters at this years EHA2021 Virtual Congress.
  • Our preclinical studies continue to elucidate the relationship between ALK2 inhibition, hepcidin and serum iron.
  • In addition, the data suggests that ALK2 inhibition has the potential to mobilize and reduce tissue iron in diseases of iron overload, said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros.

2021 Market Report on Hepcidin Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, Pharmaceutical, Medical specialties, Branches of biology, Iron metabolism, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Immune system, Hamp, Antimicrobial peptides, Liver, HEPC

The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report the pipeline Target constitutes close to 5 molecules.
  • Hepcidin is a protein encoded by the HAMP gene.
  • It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects.

Investigation Report on China's Human Serum Albumin Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 10, 2021
Surgery, Health, Blood proteins, Human serum albumin, Serum albumin, Albumin, Serum, HSA

b'The "Investigation Report on China\'s Human Serum Albumin Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this market report, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020.\nHuman Serum Albumin (HSA) is made of plasma proteins from human blood, which is mainly used to replace blood volume loss resulting from trauma such as a severe burn or an injury that causes blood loss.

Key Points: 
  • b'The "Investigation Report on China\'s Human Serum Albumin Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this market report, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020.\nHuman Serum Albumin (HSA) is made of plasma proteins from human blood, which is mainly used to replace blood volume loss resulting from trauma such as a severe burn or an injury that causes blood loss.
  • Currently, there are over 30 manufacturers in the Chinese HSA market.
  • The CAGR of the sales value of Human Serum Albumin in China is 9.3% from 2016 to 2020.
  • The analyst analyzes that as the epidemic situation has been improved and the hospitals resume their operation, sales of HSA will have a recovery growth from 2021 to 2025.\n2 Sales of Human Serum Albumin in China, 2016-2020\n2.3 Sales of Human Serum Albumin by Dosage Form in China, 2016-2020\n3 Analysis of Major Human Serum Albumin Manufacturers in China, 2016-2020\n3.6 Shandong Taibang Biological Products Co., Ltd.\n4 Prices of Human Serum Albumin for Different Manufacturers in China, 2020-2021\n'

DGAP-News: Biotest AG: Biotest accelerates fibrinogen phase III study with additional patient group

Retrieved on: 
Wednesday, April 7, 2021
Blood, Coagulation system, Anatomy, Acute-phase proteins, Blood proteins, Congenital disorders, Fibrinogen, Factor I deficiency, Fibrin

In order to compensate the fibrinogen deficiency and to effectively stop bleeding, Biotest has developed the fibrinogen concentrate BT524.

Key Points: 
  • In order to compensate the fibrinogen deficiency and to effectively stop bleeding, Biotest has developed the fibrinogen concentrate BT524.
  • The AdFIrst study is a prospective, randomized, active-controlled, multicenter phase III study that investigates the efficacy and tolerability of the fibrinogen concentrate BT524 in patients with acquired fibrinogen deficiency.
  • With the AdFIrst study in acquired fibrinogen deficiency, Biotest is further expanding its development program for the fibrinogen concentrate BT524.
  • The AdFIrst study is a prospective, active-controlled, multicentre phase III study investigating the efficacy and safety of the fibrinogen concentrate BT524 in patients with acquired fibrinogen deficiency.

Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Blood proteins, Organelles, Cytosol, Serum albumin, Serum, Albumin, Protein, Cell membrane

The study, published in Science Advances, demonstrates that CPABs can be designed to efficiently penetrate the cell membrane, disrupt an intracellular protein-protein interface, and carry an albumin-binding moiety to extend their serum half-life to therapeutically relevant levels.

Key Points: 
  • The study, published in Science Advances, demonstrates that CPABs can be designed to efficiently penetrate the cell membrane, disrupt an intracellular protein-protein interface, and carry an albumin-binding moiety to extend their serum half-life to therapeutically relevant levels.
  • This holds the promise for the creation of an entirely novel class of therapeutics with applications in oncology and beyond."
  • Complix is developing Cell Penetrating Alphabodies (CPABs) that can address disease targets present in the cytosol or in the nucleus of human cells.
  • Ghent University offers a broad range of study programs in all academic and scientific fields.

Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Blood proteins, Organelles, Cytosol, Serum albumin, Serum, Albumin, Protein, Cell membrane

The study, published in Science Advances, demonstrates that CPABs can be designed to efficiently penetrate the cell membrane, disrupt an intracellular protein-protein interface, and carry an albumin-binding moiety to extend their serum half-life to therapeutically relevant levels.

Key Points: 
  • The study, published in Science Advances, demonstrates that CPABs can be designed to efficiently penetrate the cell membrane, disrupt an intracellular protein-protein interface, and carry an albumin-binding moiety to extend their serum half-life to therapeutically relevant levels.
  • This holds the promise for the creation of an entirely novel class of therapeutics with applications in oncology and beyond."
  • Complix is developing Cell Penetrating Alphabodies (CPABs) that can address disease targets present in the cytosol or in the nucleus of human cells.
  • Ghent University offers a broad range of study programs in all academic and scientific fields.

Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial

Retrieved on: 
Tuesday, March 23, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Complement system, Medical specialties, Organ systems, Immunology, Immune system, Lectins, Blood proteins, MASP2, Lectin pathway, Mannan-binding lectin-associated serine protease-2, Mannan-binding lectin, Mannans, Omeros Corporation, Narsoplimab, the I-SPY TRIALS, Quantum Leap Healthcare Collaborative

Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.
  • The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative.
  • The pulmonary and critical care investigators leading the I-SPY COVID Trial uniformly endorsed narsoplimab and made it a high-priority candidate for the trial.
  • Narsoplimab is Omeros lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement.